|
WHAT
|
- electroCore, a commercial-stage bioelectronic medicine company, will be presenting data from the PRESTO study evaluating gammaCore for the acute treatment of migraine.
- gammaCore, electroCore’s first commercialized product, is the first FDA-cleared, non-invasive vagus nerve stimulation (nVNS) therapy administered via an easy-to-use handheld delivery system, which is currently cleared for the acute treatment of pain associated with episodic cluster headache and migraine headache.
- PRESTO was a randomized, double-blind, sham-controlled, clinical trial that supported the recent FDA release of gammaCore in migraine. This is the first time PRESTO data are being presented since this milestone.
- electroCore will also have a booth at the meeting [#1755], where attendees will be able to learn more about nVNS and gammaCore and preview the newest model of the device.
- electroCore leaders are available to not only contextualize what the data means for the migraine space but also provide insight into the company and continued research regarding therapeutic approaches for a variety of neurological and rheumatologic conditions.
|
|
WHY
|
- gammaCore provides patients with an effective option to treat as needed, without the potential side effects associated with commonly prescribed drugs for both episodic cluster headache and migraine.
- electroCore aims to improve outcomes for migraine and episodic cluster headache patients grappling with huge unmet need and reduce cost to the healthcare system.
- electroCore is a pioneer in bioelectronic medicine, a relatively new approach to treat and diagnose disease, using technology to moderate electrical activity within the body’s nervous system.
|
|
WHO
|
- electroCore executives will be available to discuss the following topics:
- Peter Staats, M.D., electroCore’s chief medical officer, can shed light on results of electroCore’s ongoing clinical trials and the potential of gammaCore in migraine and cluster headache
- Dan Duhart, electroCore’s chief commercial officer, can provide insight on gammaCore’s commercial strategy
- The following neurology experts can provide prospective on the results of the PRESTO clinical trial and the importance of new therapies for the growing migraine population
- Cristina Tassorelli, M.D., PRESTO clinical trial investigator
- Deborah Friedman, M.D., Neuro-Ophthalmologist, Dallas
- Stephen Silberstein, M.D., Director, Headache Center, Jefferson University
|
|
WHEN/WHERE
|
- PRESTO data presentation: Thursday, April 26 at 4:18 p.m. PST
- electroCore Booth #1755 at Exhibit Hall: Sunday, April 22 – Thursday, April 26 (11:30 a.m. – 4:00 p.m. PST)
|
|
MEDIA CONTACT
|
In advance: Kimberly Davidow, 215.298.9339 or 347.931.5824
On-site: Alexandra Canale, 617.921.9353
|
For gammaCore’s Important Safety Information, please visit: https://gammacore.com/about/important-safety-information/
